We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinical Crossroads | Clinician's Corner

Long-term Management of Venous Thromboembolism:  A 61-Year-Old Woman With Unprovoked Venous Thromboembolism

Kenneth A. Bauer, MD, Discussant
JAMA. 2011;305(13):1336-1345. doi:10.1001/jama.2011.361.
Text Size: A A A
Published online

Numerous randomized clinical trials have compared various durations of anticoagulant therapy with a vitamin K antagonist (ie, warfarin) for an initial episode of venous thromboembolism (VTE). Despite major advances in understanding the pathophysiology of thrombosis and its genetic basis, clinical risk factors at presentation have emerged as the primary determinant of recurrence risk. Following a minimum of 3 months of anticoagulant therapy, patients with VTE in association with transient risk factors (eg, major surgery, trauma, pregnancy) have a low annual recurrence risk, while patients without identifiable provocative risk factors have a recurrence risk of approximately 25% at 4 years with the highest annual rates occurring in the first 2 years. Extending warfarin therapy is highly effective in preventing recurrences but is associated with increased rates of major and minor bleeding. Clinical decision making therefore requires individualized assessment of recurrence and bleeding risk, coupled with patient preference. After 3 months of anticoagulant therapy for a first episode of unprovoked VTE, male sex, age older than 65 years, and an elevated D-dimer level 1 month after discontinuing anticoagulant therapy are useful parameters in identifying patients with an increased recurrence risk. The case of Ms W, a woman with unprovoked venous thromboembolism and hemorrhagic event while receiving anticoagulation, is used to illustrate clinical decision making to determine ongoing treatment.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal


Place holder to copy figure label and caption
Figure 1. Computed Tomographic Angiography of Ms W Showing Bilateral Pulmonary Emboli
Graphic Jump Location

Arrowheads indicate intraluminal filling defects within branches of the pulmonary arteries.

Place holder to copy figure label and caption
Figure 2. Risk Factors for Venous Thrombosis.
Graphic Jump Location




You need to register in order to view this quiz.
Submit a Response


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 2

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Dabigatran for the prevention and treatment of thromboembolic disorders. Expert Rev Cardiovasc Ther Published online Apr 5, 2015;
Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin. Clin Appl Thromb Hemost Published online Apr 7, 2015;

Users' Guides to the Medical Literature
How to Use a Patient Management Recommendation: Clinical Practice Guidelines and Decision Analyses

Users' Guides to the Medical Literature